These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...
In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.
The Phase III MITIGATE trial demonstrated that Uplizna (inebilizumab) significantly reduces the risk of flares, lowers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback